Willem P Stemmer

This inventor holds 40 USPTO granted patents and 23 published patent applications, plus 4 CIPO patents and 11 EPO patents, primarily in Recombinant Polypeptides. Top assignees: Amunix Operating Inc., Affymax Technologies, N.v., Maxygen, Inc.. Active years: 1994-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Willem P Stemmer. Retrieved from https://idiyas.com/inventor/willem-p-stemmer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 40 (Patent Applications = 23)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 11 (Patent Applications = 15)

Average Co-Inventor Count = 2.9

ph-index = 23

Forward Citations = 5,877(Granted Patents)

Location History:

Menlo Park, CA (US) (1994)
Los Gatos, CA (US) (1996 - 2024)

Company Filing History:

21 out of 24

Amunix Operating Inc.

patents

8 out of 88

Affymax Technologies, N.v.

Amunix Pharmaceuticals, Inc

Bioverativ Therapeutics Inc.

patents

where one patent can have more than one assignee

Years Active: 1994-2024

Loading Chart...

Areas of Expertise:

Recombinant Polypeptides

Glucose-Regulating Proteins

Coagulation Factors

Binding Fusion Proteins

Growth Hormone

Unstructured Polymers

Peptide Libraries

Polynucleotide Engineering

DNA Mutagenesis

Cellular Engineering

Protein Stability

Drug Conjugates

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12071456 - Extended recombinant polypeptides and compositions comprising same (2024-08-27),

2. 10961287 - Extended recombinant polypeptides and compositions comprising same (2021-03-30),

3. 10421798 - Factor VIII compositions and methods of making and using same (2019-09-24),

4. 10000543 - Glucose-regulating polypeptides and methods of making and using same (2018-06-19),

5. 9938331 - Biologically active proteins having increased in vivo and/or in vitro stability (2018-04-10),

6. 9926351 - Extended recombinant polypeptides and compositions comprising same (2018-03-27),

7. 9849188 - Growth hormone polypeptides and methods of making and using same (2017-12-26),

8. 9758776 - Coagulation factor IX compositions and methods of making and using same (2017-09-12),

9. 9540430 - Glucose-regulating polypeptides and methods of making and using same (2017-01-10),

10. 9376672 - Coagulation factor IX compositions and methods of making and using same (2016-06-28),

11. 9371369 - Extended recombinant polypeptides and compositions comprising same (2016-06-21),

12. 9249211 - Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same (2016-02-02),

13. 9168312 - Growth hormone polypeptides and methods of making and using same (2015-10-27),

14. 9062299 - Coagulation factor IX compositions and methods of making and using same (2015-06-23),

15. 8957021 - Glucose-regulating polypeptides and methods of making and using same (2015-02-17),

Title: **Willem P. Stemmer: Innovator in Biopharmaceuticals**

Introduction

Willem P. Stemmer, based in Los Gatos, California, is a distinguished inventor with a remarkable portfolio of 40 patents. His work primarily focuses on the field of biopharmaceuticals, particularly in the development of innovative compositions aimed at treating various medical conditions.

Latest Patents

Among his latest contributions to the field are patents related to extended recombinant polypeptides and their compositions. These inventions pertain to biologically active proteins linked to extended recombinant polypeptide (XTEN), alongside isolated nucleic acids that encode these compositions. The implications of his work are vast, targeting the treatment of glucose-related diseases, metabolic disorders, coagulation issues, and growth hormone-related complications. This innovative approach potentially revolutionizes how such conditions are managed in clinical settings.

Career Highlights

Over the years, Stemmer has been associated with notable companies in the biopharmaceutical sector, including Amunix Operating Inc. and Affymax Technologies, N.V. His role in these companies has enabled him to contribute significantly to advancements in therapeutic solutions, leading to a better understanding and treatment of complex diseases.

Collaborations

Collaboration plays a crucial role in Stemmer’s success as an inventor. He has worked alongside esteemed colleagues such as Volker Schellenberger and Chia-wei Wang. These partnerships have fostered a rich environment of shared knowledge and innovation, driving the development of groundbreaking biopharmaceutical applications.

Conclusion

Willem P. Stemmer's contributions to the field of biopharmaceuticals exemplify the impact of innovation in medicine. With 40 patents to his name, his work continues to open new avenues for the treatment of various medical conditions, underscoring the importance of inventors in advancing healthcare technology. His ongoing efforts not only reflect a commitment to innovation but also a dedication to improving patient outcomes through scientific excellence.

Profile summary based on public USPTO records.